Who
David W. J. McGirr
Director
Company insider
Files Form 4 as: Director, Rhythm Pharmaceuticals; Director, Insmed; Director, X4 Pharmaceuticals; Director, Yarrow Bioscience; Director, Roka BioScience; Director, Relypsa; SVP & Chief Financial Officer, Cubist Pharmaceuticals; Director, Lifecell.
In numbers
- Trades disclosed
- 171
- Buys
- 2
- Sells
- 15
- Bought
- $180K
- Sold
- $11.1M
- Companies
- 8
- Companies where not an officer
- 7
- First trade
- 9 Jan 2006
- Last trade
- 24 Jun 2026
- Last filed
- 25 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 24 Jun 2026filed 25 Jun 2026 | RYTM Rhythm Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —3,691 at $0.00 | filing |
| 24 Jun 2026filed 25 Jun 2026 | RYTM Rhythm Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —3,691 at $0.00 | filing |
| 24 Jun 2026filed 25 Jun 2026 | RYTM Rhythm Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,324 at $0.00 | filing |
| 24 Jun 2026filed 25 Jun 2026 | RYTM Rhythm Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,324 at $0.00 | filing |
| 23 Jun 2026filed 25 Jun 2026 | RYTM Rhythm PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —4,712 | filing |
| 23 Jun 2026filed 25 Jun 2026 | RYTM Rhythm Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —4,712 at $0.00 | filing |
| 23 Jun 2026filed 25 Jun 2026 | RYTM Rhythm Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —4,712 at $0.00 | filing |
| 23 Jun 2026filed 25 Jun 2026 | RYTM Rhythm PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —4,712 | filing |
| 9 Feb 2026filed 11 Feb 2026 | INSM InsmedBiotechnology | SEC FORM 4 Code G | —53,400 at $0.00 | filing |
| 9 Feb 2026filed 11 Feb 2026 | INSM InsmedBiotechnology | SEC FORM 4 Code G | —53,400 at $0.00 | filing |
| 9 Feb 2026filed 11 Feb 2026 | INSM InsmedBiotechnology | SEC FORM 4 Code G | —53,400 at $0.00 | filing |
| 9 Feb 2026filed 11 Feb 2026 | INSM InsmedBiotechnology | SEC FORM 4 Code G | —53,400 at $0.00 | filing |
| 24 Jun 2025filed 26 Jun 2025 | RYTM Rhythm Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —7,037 at $0.00 | filing |
| 24 Jun 2025filed 26 Jun 2025 | RYTM Rhythm Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —4,712 at $0.00 | filing |
| 18 Jun 2025filed 23 Jun 2025 | RYTM Rhythm Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —4,000 at $0.00 | filing |
| 18 Jun 2025filed 23 Jun 2025 | RYTM Rhythm PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —4,000 | filing |
| 9 Jun 2025filed 10 Jun 2025 | XFOR X4 PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —1,500 at $0.00 | filing |
| 4 Jun 2025filed 4 Jun 2025 | INSM InsmedBiotechnology | SEC FORM 4 Sold | $220K3,000 at $73.27 | filing |
| 3 Jun 2025filed 5 Jun 2025 | RYTM Rhythm Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —65,431 at $0.00 | filing |
| 3 Jun 2025filed 5 Jun 2025 | RYTM Rhythm PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $300K65,431 at $4.59 | filing |
News
Rhythm Pharmaceuticals Announces Commercial Launch of IMCIVREE® (setmelanotide) in Japan for Patients with Acquired Hypothalamic ObesityRYTM · manilatimes.net · 14 Oct 2026
0 headlines in the last 90 days name David W. J. McGirr; 1 article from the last 14 days about the 2 companies they traded most, at most three about any one of them.